POGZ truncating alleles cause syndromic intellectual disability

Janson White1†, Christine R. Beck1†, Tamar Harel1, Jennifer E. Posey1, Shalini N. Jhangiani2, Sha Tang3, Kelly D. Farwell3, Zöe Powis3, Nancy J. Mendelsohn4, Janice A. Baker4, Lynda Pollack5, Kati J. Mason5, Klaas J. Wierenga6, Daniel K. Arrington6, Melissa Hall6, Apostolos Psychogios7, Laura Fairbrother7, Magdalena Walkiewicz1,8, Richard E. Person1,8, Zhiyv Niu1,8, Jing Zhang1,8, Jill A. Rosenfeld1,8, Donna M. Muzny2, Christine Eng1,8, Arthur L. Beaudet1,10, James R. Lupski1,2,9,10, Eric Boerwinkle2,11, Richard A. Gibbs1,2, Yaping Yang1, Fan Xia1,8 and V. Reid Sutton1*

Abstract

Background: Large-scale cohort-based whole exome sequencing of individuals with neurodevelopmental disorders (NDDs) has identified numerous novel candidate disease genes; however, detailed phenotypic information is often lacking in such studies. De novo mutations in pogo transposable element with zinc finger domain (POGZ) have been identified in six independent and diverse cohorts of individuals with NDDs ranging from autism spectrum disorder to developmental delay.

Methods: Whole exome sequencing was performed on five unrelated individuals. Sanger sequencing was used to validate variants and segregate mutations with the phenotype in available family members.

Results: We identified heterozygous truncating mutations in POGZ in five unrelated individuals, which were confirmed to be de novo or not present in available parental samples. Careful review of the phenotypes revealed shared features that included developmental delay, intellectual disability, hypotonia, behavioral abnormalities, and similar facial characteristics. Variable features included short stature, microcephaly, strabismus and hearing loss.

Conclusions: While POGZ has been associated with neurodevelopmental disorders in large cohort studies, our data suggest that loss of function variants in POGZ lead to an identifiable syndrome of NDD with specific phenotypic traits. This study exemplifies the era of human reverse clinical genomics ushered in by large disease-directed cohort studies; first defining a new syndrome molecularly and, only subsequently, phenotypically.

Background

Neurodevelopmental disorders (NDDs) reflect a molecularly and phenotypically heterogeneous classification encompassing intellectual disability (ID), microcephaly, and neurobehavioral traits such as autism spectrum disorder (ASD) [1]. Collectively, these traits are quite common, with ASD having a prevalence of ~1 % and ID occurring in ~2–3 % of the population. The delineation of various NDDs is not discrete, as more than one phenotype is often present in an individual. Whole exome sequencing (WES) has revealed that mutations in the same gene may be associated with a broad spectrum of neurobehavioral and neurodevelopmental phenotypes [2, 3].

The clinical and genetic heterogeneity of ASD and other neurobehavioral traits represents a challenge for both molecular diagnoses and new gene discovery [4]. ASD is characterized by impairment in social interaction as well as restricted and stereotyped patterns of interest and activities, and is often accompanied by ID and language delay. Recent advances in personal genome analysis and the assembly of large cohorts for study have begun to identify potentially pathogenic variants in individuals with ASD; however, the majority of ASD loci have yet to be identified and may include gene-
We have identified five POGZ disrupting mutations in patients with diverse clinical assessments. These individuals have variable NDDs with shared features comprising ID, global DD, behavioral abnormalities, microcephaly, short stature, strabismus, and shared facial characteristics. Together with eight pathogenic mutations from the literature, we describe the spectrum of phenotypes in individuals with deleterious mutations in POGZ. Ascertainment of patients with a shared molecular diagnosis and subsequent phenotypic characterization delineates the clinical presentation common to individuals with POGZ mutations. This genotype-driven approach may be especially relevant for the variable presentations of NDDs, and can be used to further clinically characterize candidate genes identified in diverse cohort studies.

Methods
This study conforms to the Helsinki Declaration and was performed with approval by the Baylor College of Medicine institutional review board, protocol number H-29697, for all sequencing conducted at the Baylor College of Medicine Human Sequencing Center. Written informed consent was obtained from the parents/legal guardians of the patients for publication of this research and any accompanying images. Exome sequence analysis across all sequencing centers followed the guidelines and process for classifying sequencing variants developed by the American College of Medical Genetics and Genomics [23]. Trio-based sequencing allowed for the prioritization of de novo loss-of-function mutations in four patients. An average of 2.5 de novo mutations were identified in each proband, of which POGZ was the only truncating allele. Additionally, variants in POGZ were selected for confirmation and co-segregation with the phenotype because loss-of-function mutations in this gene have been found in large cohorts of individuals with neuropsychiatric phenotypes. All identified variants in POGZ have been deposited into ClinVar under accession numbers SCV000256903, SCV000256904, SCV000256905, SCV000256906, and SCV000256907 in agreement with institutional review board approval and patient consent.

DNA from patient 1 and her mother was subjected to WES at the BCM Human Genome Sequencing Center through the Baylor-Hopkins Center for Mendelian Genomics initiative. Exome sequencing and analysis were performed according to previously described methods [24]. Potential de novo mutations were identified in silico by subtracting variants observed in the mother from those observed in patient 1. Candidate variants were filtered against exome data in publicly available databases, including the 1000 Genomes Project, the National Heart, Lung, and Blood Institute Exome Sequencing Project (ESP), the Atherosclerosis Risk in Communities Study (ARIC)
database (http://www2.cscc.unc.edu/aric), and our in-house-generated database of approximately 5000 exomes.

Patients 2 and 3 were identified through diagnostic WES at the Baylor-Miraca Medical Genetics Laboratory. Sequencing and data analysis were conducted as previously described [25]. Briefly, the average coverage for ~20,000 targeted genes (42 Mb of targeted regions, including untranslated exons) was greater than 100×, and more than 95% of the target bases were covered by at least 20 reads [26].

Patients 4 and 5 were identified via diagnostic exome sequencing at Ambry Genetics (Aliso Viejo, CA, USA). Sequencing and data analysis at Ambry Genetics were conducted as previously described [27]. The mean coverage across the parent–proband trio of patient 4 and patient 5 was greater than 90× with >91% of the targeted bases covered at >20×.

PCR amplification and Sanger sequencing to verify all candidate mutations were done according to standard procedures and candidate variants were annotated using the POGZ RefSeq transcript NM_015100.3. Parental samples, when available, were also tested via standard Sanger sequencing.

Results
Clinical reports
Characteristic clinical findings are summarized in Table 1.

Patient 1 is a 15-year-old female who initially presented in infancy with global DD. She walked at 17 months and her first words were at 18 months. She had a developmental assessment done at 5 years 8 months of age, at which time her motor skills were at age level with a performance IQ of 70, overall IQ of 50, and full scale IQ of 56. Behavioral abnormalities were apparent before 2 years of age, and as she developed, her psychiatric symptoms became more pronounced and included aggressive behavior, self-injury and property destruction that necessitated multiple inpatient psychiatric admissions. Other medical issues included a disturbed sleep cycle that responded to melatonin, mild obstructive sleep apnea, early-onset obesity, and mild myopia. On physical examination at 15 years, her weight was 80.7 kg (97th percentile), height was 152 cm (6th percentile), and head circumference was 52.1 cm (~2 standard deviations). Her body mass index was 34.9 kg/m² (99th percentile). Facial characteristics include brachycephaly, a long and flat malar region, broad and depressed nasal tip, short philtrum, thin vermillion border, downturned corners of the mouth and pointed chin. She had generalized hypotonia with a mildly wide-based and waddling gait. Brain magnetic resonance imaging (MRI), electroencephalogram, and audiometry were normal. She was initially suspected to have Smith-Magenis syndrome due to sleep disturbance and global DD but high-density aCGH for chromosome 17p11.2 was normal. Molecular testing revealed a novel missense variant in RAI1 (NM_030665.3.c.4103A>G, p.S1212G) [28]. This variant was predicted to be benign and polymorphic by PolyPhen-2 and MutationTaster, and is poorly conserved in mammalian evolution. However, the variant was inherited from her father who had a history of learning disability and a personality disorder, and is shared with her sister who had clinical features suggestive of Smith-Magenis syndrome [28]. Thus, we could not conclusively rule out that this missense variant in RAI1 is contributing to the phenotype present in patient 1, but her more severe developmental disability compared with her father and sister warranted further work-up. Additional diagnostic evaluation was noncontributory and included chromosome analysis, fluorescent in situ hybridization (FISH) for 22q11.2 deletion, MECP2 sequencing, fragile X testing, lead levels, thyroid function studies, plasma amino acids and urine organic acids. Due to the equivocal interpretation of the RAI1 variant, research exome sequencing was undertaken.

Patient 2 is a 31-month-old female with microcephaly, short stature, global DD, non-ocular visual impairment, failure to thrive and multiple congenital abnormalities, including diaphragmatic hernia and a duplicated renal collecting system. Initial echocardiogram showed a patent ductus arteriosus and a patent foramen ovale or atrial septal defect, which resolved without surgical intervention. Physical examination revealed brachycephaly, sparse hair, low-set and posteriorly rotated ears, long malar region, hypertelorism with downslanting palpebral fissures, a flat nasal bridge, with a broad and depressed nasal tip, short philtrum, thin vermillion border, downturned corners of the mouth, pointed chin, and a short neck with mild webbing. A full psychological and developmental assessment was performed at two years of age. According to the Mullen Scales of Early Learning her visual reception was within the 20th percentile, fine motor was within the 20th percentile, receptive language was within the 20th percentile, and expressive language was within the 20th percentile. According to the Vineyard adaptive behavior scales her communication skills were below the first percentile, daily living skills were below the first percentile, socialization was within the first percentile, motor skills were below the first percentile, and adaptive behavior were below the first percentile. Collectively, the results of her formal assessment indicate significant delays across all areas with relative weakness in expressive language skills. Brain MRI showed nonspecific delayed myelination and diffuse T2 hyperintensity. Skeletal anomalies included multiple Wormian bones and mild hypoplasia of the cervical vertebral bodies. Previous work-up included chromosome analysis and aCGH which were normal as well as very long chain
| Patient ID | 1 | 2 | 3 | 4 | 5 | Patients reported in literature (8) |
|------------|---|---|---|---|---|-----------------------------------|
| Genotype   | Exon 15 (CDS 14) | Exon 19 (CDS 18) | Exon 6 (CDS 5) | Exon 19 (CDS 18) | Exon 19 (CDS 18) | c.2321_2324delCTCT c.2763dupC c.833C > G c.2935C > T c.2780dupT Frameshift or stopgain (7); missense (1) |
| Effect     | p.Ser774Cysfs*16 | p.Ser278* | p.Arg979* | p.Leu927Phefs*17 |
| Exon number| Not maternal | + | + | + | + | 8/8 |
| Age at evaluation | 15 years | 19 months | 3 years 10 months | 5 years | 4 years 7 months |
| Gender | F | F | M | F | F | M (3); F (2); NR (3) |
| Paternal age | NA | 45 years | 28 years | NA | 30 years |
| DD/ID | + | + | + | + | + | + (7); NR (1) |
| Behavioral phenotype | + | + | + | NA | + |
| ASD | NA | - | + | NA | + | ASD (4); schizophrenia (1); psychiatric abnormality (1) |
| Hearing loss | - | SNHL | NA | SNHL | SNHL | + (1); NR (7) |
| Vision | Mild myopia | Cortical blindness | Astigmatism, hyperopia | Rod-cone dystrophy, anisometropia | Astigmatism |
| Seizures | - | - | Complex partial seizures | - | - | 1 (with hypoglycemia); NR (7) |
| Gl manifestations | NA | + | + | + | + | + (1); NR (7) |
| Stature <10th percentile | + | + | - | + | + | + (2); NR (6) |
| Microcephaly | - | + | - | + | + | + (1); NR (7) |
| Brachycephaly | + | - | - | + | + | |
| Midface hypoplasia | + | - | - | + | + | |
| Strabismus | - | + | + | + | + | + (1); NR (7) |
| Optic nerve hypoplasia | - | - | - | + | + | |
| Long and flat malar region | + | + | + | + | + | |
| Flat nasal bridge | + | + | - | - | - | + (1); abnormal outer ear; NR (7) |
| Broad nasal tip | + | + | + | + | + | |
| Short philtrum | + | + | + | + | + | |
| Thin vermilion border | + | + | + | - | + | |
| Downturned corners of the mouth | + | + | + | + | + | |
| Palate abnormality | High arched palate | - | Bifid uvula | High arched palate | Cleft palate, high arched palate |
| Pointed chin | + | + | - | + | + | |
| Ears | Over-folded superior helices | Low set, posteriorly rotated | - | Posteriorly rotated | - | + (1; abnormal outer ear); NR (7) |
fatty acids. A clinical concern for Pallister-Killian was entertained at birth due to facial features and congenital diaphragmatic hernia.

Patient 3 is a 3-year 10-month-old male with global DD, complex partial seizures and behavioral abnormalities concerning for ASD. He first presented at two months of age due to poor weight gain and poor suck and latch. At 34 months of age, DAYC-2 formal developmental assessment was administered and he scored a General Developmental Index of 67, interpreted as significantly below age-level across all areas. His full scale IQ at 34 months was 71 (third percentile), verbal comprehension was 85 (14th percentile) and non-verbal abilities were 64 (first percentile). Physical examination revealed strabismus, bifid uvula, a wide space between the central incisors, brachydactyly, large thumbs, broad feet, and large toes. Ophthalmology exam at 12 months of age detected hyperopia and astigmatism. Family history was significant for seizures on the maternal side. He has complex partial seizures localizing to the left fronto-parietal area. He was initially treated with phenobarbital but switched to levetiracetam and was well-controlled. Due to concern that this drug was contributing to his behavioral issues, the patient was switched to oxcarbazepine. He developed tic-like movements after the second dose and it was stopped. Topiramate was added and he did start having new seizures while he was on both topiramate and levetiracetam but controlled with higher doses of topiramate. Levetiracetam was eventually weaned and the irritability has improved. Previous workup was unrevealing and included chromosome analysis, aCGH, metabolic testing, Angelman methylation studies and CREBBP and EP300 testing for Rubinstein-Taybi syndrome I and II.

Patient 4 is a 5-year-old female with microcephaly, short stature, global DD, and a history of low muscle tone. Additional medical concerns included feeding difficulties, severe gastroesophageal reflux disease, sensorineural hearing loss, exotropia, and obstructive sleep apnea. Facial characteristics included brachycephaly, a sloping broad forehead, posteriorly rotated ears, upslanting palpebral fissures, long and flat malar region, broad and depressed nasal tip, short philtrum, downturned corners of the mouth, high palate, pointed chin, and relative prognathia. Ophthalmology exam showed exotropia, anisometropia, optic nerve hypoplasia, and rod-cone retinal dystrophy. Brain MRI showed optic nerve hypoplasia with no other structural abnormalities. Skeletal survey was normal other than significant brachycephaly. At age 27 months she underwent a developmental assessment. According to both the Clinical and Auditory Milestones Scale and Cognitive adaptive test she scored at a basal level of 6 months, indicating severe delays across all areas of development with most significant delays to her acquisition of speech and language. Previous molecular testing included aCGH, which revealed a paternally inherited 125-kb copy number gain within chromosome 12q24.12; she had a normal chromosome analysis, an unrevealing targeted microcephaly gene panel, and normal thyroid function studies, plasma amino acids, urine organic acids, and urine mucopolysaccharides.

Patient 5 is a 4-year 7-month-old female with microcephaly, cleft palate, global DD, hypotonia and ASD. She presented at birth with cleft palate, micrognathia and a

### Table 1 Phenotypic and molecular data (Continued)

| Phenotypic Feature | Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 |
|--------------------|-----------|-----------|-----------|-----------|-----------|
| Micrognathia       | -         | -         | -         | -         | + (infancy) |
| Prognathism        | +         | -         | -         | -         | + (toddler) |
| Short neck         | +         | +         | -         | -         | -         |
| Brachydactyly      | -         | -         | +         | -         | +         |
| Joint laxity       | +         | +         | -         | -         | -         |
| Hypotonia          | +         | +         | +         | -         | + (1); NR (7) |
| Brain MRI          | No structural anomalies | Diffuse T2 hyperintensity, delayed myelination | No structural anomalies | No structural anomalies | Dandy-Walker variant; decreased white matter; enlarged third and fourth ventricles +1 (thin corpus callosum); NR (7) |
| Sleep apnea        | -         | -         | -         | +         | -         |
| Congenital malformations | - | Congenital diaphragmatic hernia; PDA, PFO/ASD; duplicated renal collecting system | - | - | PFO; left duplicated renal collecting system |

**Abbreviations:** ASD atrial septal defect, GI gastrointestinal, F female, M male, MRI magnetic resonance imaging, NA not available, NR not reported, PDA patent ductus arteriosus, PFO patent foramen ovale, SNHL sensorineural hearing loss

*Patient 1 was previously reported as patient 2 in Bi et al. [28]*
duplicated renal collecting system. Facial and physical characteristics included broad forehead, brachycephaly, broad and depressed nasal tip, short philtrum, thin vermilion border, downturned corners of the mouth, pointed chin, and small hands with relative brachydactyly. Upon her initial clinical presentation additional features were noted, including auditory neuropathy, immune deficiency, and left duplicated renal collecting system. Ophthalmology exam showed exotropia, astigmatism and small optic nerves. Brain MRI revealed Dandy-Walker variant, decreased white matter, and enlarged third and fourth ventricles. Her original exome report identified compound heterozygous variants of unknown clinical significance in STIL, associated with primary microcephaly. Additionally, microarray revealed a paternally inherited Xq21.1 duplication. Previous normal testing included chromosome analysis, FISH for 22q11 deletion, methylation studies for Prader Willi and Angelman syndromes, and ROR2 sequencing. Other testing, all normal, included urine organic acids, serum amino acids, acylcarnitine, and very long chain fatty acids.

**Phenotypic spectrum**

The clinical description of the individuals in this study overlaps with the descriptions of previously reported patients [15–20]. All five subjects had global DD and/or ID. Behavioral abnormalities ranged from self-injurious behavior to high-functioning ASD. Additional common features included microcephaly (3/5), stature below the tenth percentile (4/5), hypotonia (4/5), strabismus (4/5), vision abnormalities (5/5), sensorineural hearing loss (3/5), and gastrointestinal manifestations including poor feeding, gastroesophageal reflux, and/or constipation (4/5). Recurrent facial and physical characteristics included hypotonic faces with an open mouth, brachycephaly (4/5), long and flat malar region (4/5), posteriorly rotated ears (2/5), broad nasal tip (5/5), flat nasal bridge (3/5), short philtrum (5/5), thin vermilion border (4/5), downturned corners of the mouth (4/5), high arched palate (3/5), and pointed chin (4/5). An overview of clinical features is presented in Table 1. Pictures of the five patients are shown in Fig. 1.

**Genomic analyses**

To date, seven de novo mutations leading to premature termination of POGZ have been identified in cohorts of individuals with diverse NDDs, including ASD (N = 3), ID (N = 6), DD (N = 2), or schizophrenia (N = 1) [15–20]. The truncating variants result in termination of the protein prior to or within the C-terminal DDE and/or coiled-coil domains. Additionally, a de novo nonsense mutation in the CENP-B like DNA binding domain of POGZ was also reported in a child with ASD, ID and dysmorphic features (Fig. 2) [21].

We identified five patients with heterozygous truncating mutations in POGZ. Four of the five variants were confirmed to be de novo in the affected individual; the father of patient 1 was unavailable for analysis but his mother did not harbor the POGZ variant. Extensive testing for each of these individuals was negative, with the exception of a paternally inherited missense variant in RAII in patient 1 of uncertain clinical significance [28] and compound heterozygous variants of uncertain clinical significance in STIL in patient 5. We identified heterozygous truncating variants in POGZ in all five individuals by WES; these five variants were validated by Sanger sequencing (Fig. 2). Publicly available databases, including ARIC and the Exome Aggregation Consortium (ExAC; version 0.3; Cambridge, MA, USA; http://exac.broadinstitute.org) confirmed that the identified variants are unique to our patients. Table 2 provides a molecular description of variants identified in these five patients and eight previously identified cases. Indels resulting in frameshift mutations were present in three of five patients and two of five contained nonsense mutations (one transition and one transversion). Three of the five variants occur in the final exon of POGZ and can potentially escape nonsense-mediated decay. However, the two patients with variants predicted to be subject to degradation by nonsense-mediated decay do not have distinguishing phenotypic features from the three terminal exon-containing patients. All five truncating mutations are predicted to result in the loss of greater than 402 amino acids at the C-terminus of POGZ. Loss of this region of the protein is predicted by conceptual translation to result in deletion of the CENP-B like DNA binding domain, the DDE domain and the coiled-coil domain. Thus, the mutations present in each of the five individuals in this study likely result in loss of function. The assertion that heterozygous loss of function mutations in POGZ cause diverse NDDs is further supported by the presence of two CNVs encompassing POGZ coding regions in the DECIPHER database [29]. The two individuals with small deletions of POGZ are phenotypically described as having DD and additional significant developmental and morphological phenotypes.

**Discussion**

Large cohort studies have associated truncating mutations in POGZ with behavioral abnormalities, ID, and DD [16–21]. The identification of numerous candidate genes in these studies highlights their value. However, to thoroughly describe the clinically relevant phenotypes associated with mutation in a given gene, targeted analyses of a molecularly defined cohort are required. Here, we utilized a genotype-first approach to identify shared
facial and physical characteristics as well as the spectrum of individual phenotypes resulting from deleterious mutations in \textit{POGZ}.

We identified five patients with novel truncating mutations in \textit{POGZ}, likely resulting in loss-of-function alleles. The description of the five individuals and a review of eight patients from the literature indicate that individuals with mutations in \textit{POGZ} are likely to have global DD, microcephaly, ID, strabismus and variable hearing loss. Comparison of facial and physical characteristics in our five subjects has revealed shared facial features, including brachycephaly, long and flat malar region, broad nasal tip, short philtrum, thin vermillion border, downturned corners of the mouth and pointed chin (Fig. 1). Patients also present with highly variable neurobehavioral phenotypes, ranging from ASD to severe aggressive behaviors similar to what is seen in individuals with Smith-Magenis syndrome (Table 1).

It is possible that patient 1 and patient 2 may have a blended phenotype; patient 1 has a paternally inherited missense mutation in \textit{RAI1}, which is associated with Smith-Magenis syndrome. In addition to the characteristic features, patient 2 also presented with congenital abnormalities, including diaphragmatic hernia, a renal tract anomaly, and heart defects. Other than the de novo \textit{POGZ} mutation, we did not identify additional molecular events that would account for her phenotype. Therefore, although it is possible that \textit{POGZ} truncating mutations could lead to clinical phenotypes including mild congenital abnormalities, an additional unidentified cause in patient 2 could potentially be responsible for her uncharacteristic presentations. Together, our data and a literature review indicate that damaging variants in \textit{POGZ} result in a broad range of features distinguished by global DD, ID, neurobehavioral abnormalities (most often ASD), short stature, hypotonia,
Fig. 2: Locations and chromatograms of variants identified. a) The functional protein domains of POGZ. Functional protein domains include zinc-finger domains (orange and yellow), a predicted proline-rich domain (red), CENP-B like DNA binding domain (green), DDE transposase domain (blue) and a coiled-coil domain (purple). The seven truncating mutations and one deleterious missense previously reported are indicated by stars above the predicted domains. b) Truncating mutations identified in the current study are indicated at their respective locations on the protein with arrows, and the chromatograms displaying each mutation are presented below the details of the individual nucleotide and amino acid changes.
strabismus, characteristic facial features, including brachycephaly, long and flat malar region, broad nasal tip, short philtrum, thin vermillion border, downturned corners of the mouth, and pointed chin, and variable hearing loss.

POGZ has not been extensively characterized; the protein product contains eight canonical C2H2-like zinc finger domains that are implicated in protein–protein interactions and have the potential for DNA interactions [30]. The C-terminus of the protein contains a B-like centromere binding domain and a DDE domain (Fig. 2). Interestingly, POGZ interacts with HP1α via the zinc finger domain; this activates Aurora B kinase, indicating a potential role for POGZ in mitotic progression and neuronal differentiation [22]. Similar to POGZ, many genes encoding proteins required for proper centrosomal function or chromosome segregation are mutated in patients with microcephaly, demonstrating a common theme of aberrant neuronal proliferation and migration [1, 31].

POGZ is expressed in developing cortical projection neurons which have been implicated in a network convergence of neurodevelopmental risk genes [32]. HP1α also strongly interacts with NIPBL, which is mutated in individuals with Cornelia de Lange syndrome. The overlapping molecular networks of POGZ and NIPBL may indicate common mechanisms of transcriptional dysregulation with deleterious mutation of these genes [24].

Although NDDs are typically a clinical diagnosis, molecular genetic testing, including both aCGH and WES, is capable of more precisely defining syndromes and disorders with highly variable phenotypes [33]. With the expanding number of single-gene candidates for NDDs and the variability of these phenotypes, WES was crucial in defining the cohort of five patients presented here. The increasing emergence of candidate genes for various disorders necessitates genotype-driven approaches for describing associated phenotypic spectrums. Furthermore, with a better understanding of the clinical presentations of patients with deleterious POGZ mutations, more molecular diagnoses may be forthcoming.

**Conclusions**

We report the detailed phenotypic features associated with loss of function variants in POGZ. These include a broad range of features distinguished by global DD, microcephaly, ID, neurobehavioral abnormalities (including ASD), short stature, hypotonia, strabismus and variable hearing loss. We also describe characteristic facial features of this disorder that include brachycephaly, long and flat malar region, broad nasal tip, short philtrum, thin vermilion border, downturned corners of the mouth, and pointed chin. Identification of POGZ variants and subsequent description of characteristic clinical presentations demonstrate the utility of human reverse genetics in an era of personal genome analyses and clinical genomics.

**Abbreviations**

aCGH: Array comparative genomic hybridization; ASD: Autism spectrum disorder; CNV: Copy number variant; DD: Developmental delay; FISH: Fluorescent in situ hybridization; ID: Intellectual disability; MRI: Magnetic resonance imaging; NDD: Neurodevelopmental disorder; WES: Whole-exome sequencing; WGS: Whole-genome sequencing.

**Competing interests**

J.R.L. has stock ownership in 23andMe, is a paid consultant for Regeneron Pharmaceuticals, has stock options in Lasergen, Inc., is a member of the Scientific Advisory Board of Baylor Miraca Genetics Laboratories, and is a co-inventor on multiple United States and European patents related to molecular diagnostics for inherited neuropathies, eye diseases and bacterial genomic fingerprinting. Baylor College of Medicine (BCM) and Miraca Holdings Inc. have formed a joint venture with shared ownership and governance of

---

**Table 2** Molecular data for all individuals with variants in POGZ

| Citation                      | Patient ID | Gender | Age of evaluation | De novo     | Genotype | Protein change | Exon |
|-------------------------------|------------|--------|-------------------|-------------|----------|----------------|------|
| This study                    | 1          | F      | 1.6 years         | Not maternal | c.2321_2324delCTCT | p.Ser774Cysfs*16 | 15/19 |
|                               | 2          | F      | 1.7 years         | +           | c.2763dupC   | pThr922Hisfs*22  | 19/19 |
|                               | 3          | M      | 3.8 years         | +           | c.833C > G    | pSer278*       | 6/19  |
|                               | 4          | F      | 5.1 years         | +           | c.2935C > T   | p.Arg979*      | 19/19 |
|                               | 5          | F      | 4 years           | +           | c.2780dupT    | p.Leu927Phefs*17 | 19/19 |
| Previously reported           |            |        |                   |             |           |                |      |
| Fukai et al. (2015) [21]      | M          | 5 years | +                 | c.3118G > A  | p.E1040K*    |                | 19/19 |
| Lossifov et al. (2014) [17]   | M          | NR     |                   | c.3022C > T  | p.Arg1008*   |                | 19/19 |
| Lossifov et al. (2012) [18]   | M          | NR     |                   | c.3600_3607dupTGATGACG | p.Glu1203Valfs*28 |                | 19/19 |
| Neale et al. (2012) [19]      | F          | NR     |                   | c.2459_2462dupGTAC | p.Phe822Tyrfs*43 |                | 17/19 |
| Fromer et al. (2014) [20]     | F          | NR     |                   | c.3936delT    | p.Le1312Metfs*7 |                | 19/19 |
| Gilissen et al. (2014) [34]   | NR         | NR     |                   | c.3001C > T   | p.Arg1001*   |                | 19/19 |
| Deciphering Dev. Disorders (2015) [35] | NR | NR | + | c.2711 T > A | p.Leu904* | 19/19 |
|                               |            |        |                   | c.3354delC    | p.Leu1119Cysfs* | 19/19 |

F female, M male, NR not reported
the Baylor Miraca Genetics Laboratories (BMGL), which performs clinical exome sequencing. The Department of Molecular and Human Genetics at Baylor College of Medicine derives revenue from the chromosomal microarray analysis (CMA) and clinical exome sequencing offered in the Baylor Miraca Genetics Laboratory (BMGL; http://www.bmgl.com/BMGL/Default.aspx). S.T., K.F.H., and Z.P. are employed by and receive a salary from Ambry Genetics. Exome sequencing is among the commercially available tests available at Ambry Genetics. The remaining authors declare that they have no competing interests.

Authors’ contributions
J.W. and C.R.B. analyzed the data and wrote the manuscript. T.H. and V.R.S. organized phenotype assessment and supervised the study. J.E.P., S.N.J., C.E., A.L.B., J.R.L., D.M.M., E.B., R.A.G., Y.Y., and F.X. generated and advised on data analysis. S.T., K.D.F., Z.P., N.J.M., J.A.B., L.P., K.M., K.J.W., D.K.A., M.H., A.P., I.F., M.W., R.E.P., Z.N., J.Z., and J.A.R. identified and collected patients. All authors have read and approved the final manuscript.

Acknowledgements
We thank the patients and families for their contribution to this study. This work was supported by the US National Human Genome Research Institute (NHGRI)/National Heart Lung and Blood Institute (NHLBI) grant number HG006542 to the Baylor-Hopkins Center for Mendelian Genomics; the Smith-Magenis Syndrome Research Foundation (SMSRF); the National Institute of Neurological Disorders and Stroke (NINDS) NS058025; National Institute of General Medical Sciences Grant Number T32GM08307, the National Institute of Child Health and Development (NICHD) HD024064 Intellectual and Developmental Disabilities Research Center (IDDRC). C.R.B. is an HHMI fellow of the Damon Runyon Cancer Research Foundation (DRG 2155-13). T.H. and J.E.P. are employed by and receive a salary from Ambry Genetics. The remaining authors declare that they have no competing interests.

References
1. Hu WF, Chahour M, Walsh CA. The diverse genetic landscape of neurodevelopmental disorders. Annu Rev Genomics Hum Genet. 2014;15: 195–213.
2. Williams HJ, Craddock N, Russo G, Hamshere ML, Moskvina V, Dwyer S, et al. Most genome-wide significant susceptibility loci for schizophrenia and bipolar disorder reported to date cross-traditional diagnostic boundaries. Hum Mol Genet. 2011;20:387–91.
3. Taillon-Miller J, Rosenfeld JA, Blumenthal I, Pillalamarri V, Chiang C, Helbaut A, et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. Cell. 2012;148:525–37.
4. Miles JH. Autism spectrum disorders—a genetics review. Genet Med. 2011;13: 278–94.
5. McCarthy SE, Gillis J, Kramer M, Lihm J, Yoon S, Berstein Y, et al. De novo mutations in schizophrenia implicate chromatin remodeling and support a genetic overlap with autism and intellectual disability. Mol Psychiatry. 2014;19:652–8.
6. Lupski JR. Cognitive phenotypes and genomic copy number variants. JAMA. 2015;313:2029–30.
7. Xu B, Ionita-Laza I, Roos JL, Boone B, Woodrick S, Sun Y, et al. De novo gene mutations highlight patterns of genetic and neural complexity in schizophrenia. Nat Genet. 2012;44:1365–9.
8. Ronemus M, Iossifov I, Levy D, Wigler M. The role of de novo mutations in the genetics of autism spectrum disorders. Nat Rev Genet. 2014;15:133–41.
9. Treadwell-deering DE, Powell MP. Cognitive and behavioral characterization of the Potocki-Lupski syndrome (duplication 17p11.2). J Dev Behav Pediatr. 2010;31:137–43.
10. Laje G, Morse R, Richter W, Ball J, Pao M, Smith ACM. Autism spectrum features in Smith-Magenis syndrome. Am J Med Genet Part C Semin Med Genet. 2010;154:565–62.
11. Sebat J, Lakshmi B, Malhotra D, Troge J, Lese-martin C, Walsh T, et al. Strong association fo de novo copy number mutations with autism. Science. 2007; 316:445–9.
12. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skag J, et al. Structural variation of chromosomes in autism spectrum disorder. J Hum Genet. 2008; 53:477–89.
13. Männik K, Mägi R, Macé A, Cole B, Guyatt AL, Shihab HA. Copy number variations and cognitive phenotypes in unselected populations. JAMA. 2015;313:2044–54.
14. Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. Annu Rev Med. 2012;63:35–61.
15. Fitzgerald TW, Gerety SS, Jones WD, van Kogelberg M, King DA, McRae J, et al. Large-scale discovery of novel genetic causes of developmental disorders. Nature. 2014;519:223–8.
16. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst C, van Bon BW, Willersen MH, et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511:344–7.
17. Iossifov I, O’Roak BJ, Sanders SJ, Ronemus M, Krumm N, Levy D, et al. The contribution of de novo coding mutations to autism spectrum disorder. Nature. 2014;515:216–21.
18. Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenberg J, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285–99.
19. Neale BM, Kou Y, Liu M, Ma’ayan A, Samocha KE, Sabo A, et al. Patterns and rates of exonic de novo mutations in autism spectrum disorders. Nature. 2012;485:242–5.
20. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–84.
21. Fukai R, Hiraki Y, Yofune H, Tsuruzaki Y, Nakashima M, Saito H, et al. A case of autism spectrum disorder arising from a de novo missense mutation in POGZ. J Hum Genet. 2015;60:277–9.
22. Nozawa R-S, Nagao K, Masuda H-T, Iwasaki O, Hirota T, Nozaki N, et al. Human POGZ modulates dissociation of H1alpha from mitotic chromosome arms through Aurora B activation. Nat Cell Biol. 2010;12:719–27.
23. Richards S, Aziz N, Bale S, Bick D, Das S. ACMG standards and guidelines for the interpretation of sequence variants : a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17:1–20.
24. Yuan B, Pehlivan D, Karaca E, Patel N, Chang W, Gambin T, et al. Global transcriptional disturbances underlie Cornelia de Lange syndrome and related phenotypes. J Clin Invest. 2015;125:636–51.
25. Yang Y, Muzyk DM, Reid JG, Bainbridge MN, Willis A, Ward PA, et al. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N Engl J Med. 2013;369:1502–11.
26. Yang Y, Muzyk DM, Xia F, Niu Z, Person R, Ding Y, et al. Molecular findings among patients referred for clinical whole-exome sequencing. JAMA. 2014;311:1870–9.
27. Fanwell KD, Shahmizardi L, El-Khechen D, Powis Z, Chao EC, Tippin Davis B, et al. Enhanced utility of family-centered diagnostic exome sequencing with inheritance model-based analysis: results from 500 unselected families with undiagnosed genetic conditions. Genet Med. 2015;17(7):578–86.
28. Bi W, Safi GM, Girirajan S, Shi X, Stromjou B, Firth H, et al. RA11 point mutations, CAG repeat variation, and SNP analysis in non-deletion Smith–Magenis syndrome. Am J Med Genet A. 2006;146:2454–63.
29. Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, et al. DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. Am J Hum Genet. 2009;84:524–33.
30. Bartholomeeusen K, Christ F, Hendrix J, Rain JC, Emiliani S, Benarous R, et al. Lens epithelium-derived growth factor/p75 interacts with the transposase-derived DDE domain of pogZ. J Biol Chem. 2009;284:11467–77.

31. Karaca E, Weitzer S, Pehlivan D, Shiraishi H, Gogakos T, Hanada T, et al. Human CLP1 mutations alter tRNA biogenesis, affecting both peripheral and central nervous system function. Cell. 2014;157:36–50.

32. Willsey AJ, Sanders SJ, Li M, Dong S, Tebbenkamp AT, Muhle RA, et al. Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell. 2013;155:997–1007.

33. Miller DT, Adam MP, Aradhya S, Biesecker LG, Brothman AR, Carter NP, et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. Am J Hum Genet. 2010;86:749–64.

34. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BW, Willemsen MH et al. Genome sequencing identifies major causes of severe intellectual disability. Nature. 2014;511(7509):344–7.

35. Deciphering Developmental Disorders Study. Large scale discovery of novel genetic causes of developmental disorders. Nature. 2015;519(7542):223–8.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit